Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) EBT (2016 - 2025)

Historic EBT for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$1.2 million.

  • Alaunos Therapeutics' EBT fell 321.74% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year increase of 6607.81%. This contributed to the annual value of -$4.8 million for FY2024, which is 8670.28% up from last year.
  • Latest data reveals that Alaunos Therapeutics reported EBT of -$1.2 million as of Q3 2025, which was down 321.74% from -$1.0 million recorded in Q2 2025.
  • Over the past 5 years, Alaunos Therapeutics' EBT peaked at -$755000.0 during Q4 2024, and registered a low of -$22.7 million during Q3 2021.
  • In the last 5 years, Alaunos Therapeutics' EBT had a median value of -$8.9 million in 2023 and averaged -$7.8 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 2167.58% in 2021, then surged by 9050.19% in 2024.
  • Quarter analysis of 5 years shows Alaunos Therapeutics' EBT stood at -$11.8 million in 2021, then increased by 20.21% to -$9.4 million in 2022, then increased by 15.62% to -$7.9 million in 2023, then surged by 90.5% to -$755000.0 in 2024, then plummeted by 57.22% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$1.0 million for Q2 2025, and -$1.1 million during Q1 2025.